BTIG reiterates Buy rating on Zoetis stock after Innovation Day

Zoetis shares trade at $124.44 and are down 22.6% YTD amid disappointing osteoarthritis and Simparica Trio sales, increased competition and weaker veterinary visits, even as BTIG maintained a Buy rating with a $160 target and analyst targets range $130–$200. Management outlined an R&D roadmap targeting >$5 billion in additional TAM (including a $3–4bn chronic kidney disease opportunity with approvals expected in 2027 and a $1.2–1.7bn oncology TAM with 2028–2029 approvals), and the EU granted marketing authorization for Lenivia; the company retains strong fundamentals (71.7% gross margin, liquid assets > short-term obligations) and a 15.7% dividend growth rate with 13 consecutive years of payouts. Investor concern centers on lack of 2026 revenue contribution detail and near-term margin and growth pressure, prompting several firms to lower targets or assign neutral/hold ratings.

Analysis

Market structure: Zoetis (ZTS) is the incumbent beneficiary of long-term TAM expansion (CKD $3–4bn, oncology $1.2–1.7bn) but is losing near-term share and pricing power in parasiticides/dermatology, explaining the 22.6% YTD drawdown. Veterinary visit declines create demand-side headwinds; competitors with lower-cost offerings or stronger clinic ties gain share, pressuring mix and gross margins (current 71.7% may compress toward analyst concerns for 2026).

Risk assessment: Near-term (days–months) risks center on continued revenue misses, further clinic-visit deterioration, and negative analyst revisions (targets $130–$160). Tail risks (low-probability, high-impact) include a major trial failure or safety/recall for Lenivia post-launch, which could drop shares >30%; long-term (2027–29) execution risk is clinical readouts and commercialization of pipeline assets.

Trade implications: Tactical long exposure should be calibrated to timing of approvals (first CKD approvals penciled in 2027). Use defined-risk option structures: buy 18–30 month LEAP call spreads to capture re-rating if pipeline milestones meet expectations, or sell short-dated implied-volatility via covered-call income against a starter long to harvest yield while limiting downside.

Contrarian angles: The market may be over-penalizing ZTS for cyclical clinic visitation—core fundamentals (strong liquidity, 13-year dividend streak, 15.7% dividend growth) support recovery if 2027 pipeline timelines remain intact. If vet visits normalize by mid-2025 and initial Lenivia uptake in EU is steady, a re-rate to the $150–160 range is plausible, making today’s pricing a potential buying opportunity for patient capital.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ZTS via equity and hedge with a 1:1 notional purchase of 18–30 month LEAP $130–$200 call spread (buy $130C, sell $200C) to target $150–$160 by 12–24 months; set a hard stop-loss at -15% absolute from entry or if Q3 guidance cuts materially below consensus.
• If seeking income with reduced downside, buy a 1–2% long ZTS stake and sell 3–6 month covered calls ~10% out-of-the-money to collect premium while awaiting clearer commercialization metrics for Lenivia and Simparica Trio.
• Short-term traders: avoid naked short of ZTS into upcoming quarterly reports; instead, sell short-dated (30–60 day) call spreads if implied volatility spikes >25% over historical, pocketing premium ahead of headline risk.
• Pair trade (relative value): go long ZTS and short a pet-product pure-play or high-multiple pet-services name of similar market cap by equal dollar weight to express recovery in branded pharmaceuticals vs. cyclical services—rebalance after next two quarters of vet-visit data.
• Monitor specific catalysts over next 30–90 days: Q2 sales cadence for osteoarthritis and Simparica Trio, EU Lenivia rollout metrics (units sold, reorders), and any 2026 gross-margin guidance — reduce exposure if Lenivia adoption <5k units or guidance implies >200bp margin erosion by 2026.